Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2017-11-09 Interim / Quarterly Rep…
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2017
Interim / Quarterly Report Q1 2017
2017-11-09 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a material definitive agreement regarding the extension and modification of terms of a convertible debenture. It includes details about the agreement, waiver of compliance, and references an exhibit with the letter agreement. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is an announcement of a financing-related event (debt agreement modification). Therefore, it fits best under Capital/Financing Update (CAP). The document length is 4883 characters, which is consistent with a detailed 8-K filing but not a full financial report. Confidence is high due to clear identification of the document type and content focus on financing terms.
2017-10-02 English
Annual Report 2017
Annual Report FY 2017
2017-09-28 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details entry into material definitive agreements related to financing, including convertible promissory notes and consulting agreements. It also discusses creation of direct financial obligations and unregistered sales of equity securities. The document includes exhibits of agreements and notes. There is no indication that this is a full annual or quarterly report, audit report, earnings release, or other specific report type. Instead, it is a regulatory filing announcing material events and agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (8268 characters) and detailed content support this classification with high confidence.
2017-08-15 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into material definitive agreements related to convertible promissory notes and securities purchase agreements, which are financing activities. There are no financial statements or detailed financial performance data presented, only disclosures about financing transactions and related agreements. This fits the category of Capital/Financing Update (CAP) rather than a full financial report or other categories. The document length is 7008 characters, which is sufficient for a detailed 8-K filing. Therefore, the classification is CAP with high confidence.
2017-07-28 English
Capital/Financing Update 2017
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a securities purchase agreement, issuance of a convertible promissory note, unregistered sales of equity securities, a change in ticker symbol, and references to exhibits such as investor fact sheets and presentations. There are no comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. The document primarily reports on financing activities and material definitive agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a certification, so it is not RNS or RPA. Confidence is high due to clear identification of financing-related disclosures in a Form 8-K.
2017-06-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.